Loading...

We've got a brand new version of Simply Wall St! Try it out

Orchid Ventures

CNSX:ORCD
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORCD
CNSX
CA$9M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Orchid Ventures, Inc. focuses on developing, hardware manufacturing, branding, and distributing various cannabis products. The last earnings update was 163 days ago. More info.


Add to Portfolio Compare Print
  • Orchid Ventures has significant price volatility in the past 3 months.
ORCD Share Price and Events
7 Day Returns
10%
CNSX:ORCD
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:ORCD
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
ORCD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orchid Ventures (ORCD) 10% -43.6% -66.2% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on ORCD.
  • No trading data on ORCD.
Price Volatility
Industry
5yr Volatility vs Market

ORCD Value

 Is Orchid Ventures undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Orchid Ventures is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Orchid Ventures has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Orchid Ventures. This is due to cash flow or dividend data being unavailable. The share price is CA$0.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orchid Ventures's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orchid Ventures's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ORCD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-02-28) in USD $-0.62
CNSX:ORCD Share Price ** CNSX (2019-09-19) in CAD CA$0.11
CNSX:ORCD Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.08
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orchid Ventures.

CNSX:ORCD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ORCD Share Price ÷ EPS (both in USD)

= 0.08 ÷ -0.62

-0.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orchid Ventures is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Orchid Ventures is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Orchid Ventures's expected growth come at a high price?
Raw Data
CNSX:ORCD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orchid Ventures, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orchid Ventures's assets?
Raw Data
CNSX:ORCD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-02-28) in USD $-0.60
CNSX:ORCD Share Price * CNSX (2019-09-19) in CAD CA$0.11
CNSX:ORCD Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.08
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:ORCD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ORCD Share Price ÷ Book Value per Share (both in USD)

= 0.08 ÷ -0.60

-0.14x

* Primary Listing of Orchid Ventures.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orchid Ventures has negative assets, we can't compare the value of its assets to the CA Pharmaceuticals industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Orchid Ventures's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Orchid Ventures's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Orchid Ventures has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ORCD Future Performance

 How is Orchid Ventures expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orchid Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orchid Ventures expected to grow at an attractive rate?
  • Unable to compare Orchid Ventures's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Orchid Ventures's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Orchid Ventures's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ORCD Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ORCD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ORCD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-02-28 4 -3 -2
2018-11-30 3 -2 -2
2018-08-31 3 -1 -1
2018-05-31 2 -1 -2
2017-05-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Orchid Ventures is high growth as no earnings estimate data is available.
  • Unable to determine if Orchid Ventures is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ORCD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Orchid Ventures Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORCD Past Financials Data
Date (Data in USD Millions) EPS *
2019-02-28 -0.62
2018-11-30 -0.46
2018-08-31 -0.40
2018-05-31 -0.47
2017-05-31 -0.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Orchid Ventures will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Orchid Ventures's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Orchid Ventures's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Orchid Ventures's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orchid Ventures has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ORCD Past Performance

  How has Orchid Ventures performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orchid Ventures's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orchid Ventures does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Orchid Ventures's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orchid Ventures's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Orchid Ventures's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orchid Ventures Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORCD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-02-28 3.61 -2.40 4.27 0.02
2018-11-30 3.47 -1.78 3.81 0.01
2018-08-31 3.24 -1.34 3.08 0.02
2018-05-31 2.47 -1.70 2.84 0.02
2017-05-31 -0.86 0.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orchid Ventures has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Orchid Ventures has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orchid Ventures improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Orchid Ventures's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orchid Ventures has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ORCD Health

 How is Orchid Ventures's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orchid Ventures's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orchid Ventures's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Orchid Ventures's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orchid Ventures's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Orchid Ventures has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orchid Ventures Company Filings, last reported 6 months ago.

CNSX:ORCD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-02-28 -2.34 3.50 0.34
2018-11-30 -1.45 2.45 0.36
2018-08-31 -0.78 0.79 0.12
2018-05-31 -0.63 0.13 0.07
2017-05-31 0.73 0.00 0.70
  • Orchid Ventures has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Orchid Ventures's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orchid Ventures has less than a year of cash runway based on current free cash flow.
  • Orchid Ventures has less than a year of cash runway if free cash flow continues to grow at historical rates of 56.1% each year.
X
Financial health checks
We assess Orchid Ventures's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orchid Ventures has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ORCD Dividends

 What is Orchid Ventures's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orchid Ventures dividends.
If you bought CA$2,000 of Orchid Ventures shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orchid Ventures's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orchid Ventures's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ORCD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orchid Ventures has not reported any payouts.
  • Unable to verify if Orchid Ventures's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orchid Ventures's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orchid Ventures has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Orchid Ventures's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orchid Ventures afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orchid Ventures has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ORCD Management

 What is the CEO of Orchid Ventures's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Corey Mangold
CEO Bio

Mr. Corey Mangold co-founded CR International Inc. (formerly, Orchid Essentials) in February 2017 and serves as its Chief Executive Officer & Director.

CEO Compensation
  • Insufficient data for Corey to compare compensation growth.
  • Insufficient data for Corey to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Corey Mangold

TITLE
Co-Founder

George Mattia

TITLE
Co-CEO & Director
TENURE
0.7 yrs

Rick Brown

TITLE
President & Director
AGE
59
TENURE
0.1 yrs

Adam Mirkovich

TITLE
Chief Operating Officer
AGE
34
Board of Directors

Tom Soto

TITLE
Chairman of the Board

Corey Mangold

TITLE
Co-Founder

George Mattia

TITLE
Co-CEO & Director
TENURE
0.7 yrs

Rick Brown

TITLE
President & Director
AGE
59
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Orchid Ventures's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orchid Ventures has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ORCD News

Simply Wall St News

ORCD Company Info

Description

Orchid Ventures, Inc. focuses on developing, hardware manufacturing, branding, and distributing various cannabis products. It provides cannabidiol and tetrahydrocannabinol product lines that are sold in approximately 350 dispensaries across California and Oregon. The company is based in Irvine, California.

Details
Name: Orchid Ventures, Inc.
ORCD
Exchange: CNSX
Founded:
CA$8,561,909
77,835,537
Website: http://www.orchidessentials.com
Address: Orchid Ventures, Inc.
9930 Irvine Center Drive,
Irvine,
California, 92618,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ORCD Subordinate Voting Shares Canadian National Stock Exchange CA CAD 18. Mar 2019
OTCPK ORVR.F Subordinate Voting Shares Pink Sheets LLC US USD 18. Mar 2019
MUN ORD Subordinate Voting Shares Boerse Muenchen DE EUR 18. Mar 2019
Number of employees
Current staff
Staff numbers
0
Orchid Ventures employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:26
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/04/10
Last earnings reported: 2019/02/28
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.